drugset
drugset / Trial / NCT00444522

Staccato Alprazolam Single Dose PK

NCT00444522 ↗

Phase 1 Completed 50 enrolled Alexza Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

We are developing Staccato Alprazolam for the acute treatment of panic attacks associated with panic disorder.

Timeline

Start
2005-06
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Alprazolam Small molecule — Inhaled

Indications

No indication recorded.